Marshall Wace
VYNE icon

Marshall Wace’s VYNE Therapeutics VYNE Stock Holding History

Marshall Wace’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,165
Closed -$169K – 4080
2021
Q4 		$169K Buy
+9,165
New +$197K ﹤0.01% 3222
2021
Q2 		– Sell
-3,591
Closed -$442K – 3133
2021
Q1 		$442K Buy
+3,591
New +$521K ﹤0.01% 1993

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Marshall Wace's VYNE Position: Q1 2022 in Review

Marshall Wace sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 9,165 shares — an estimated $169K sold.

Marshall Wace first reported a position in VYNE in Q1 2021 and held it in 2 quarters. The position peaked at $442K in Q1 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

  • Marshall Wace reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 9,165 VYNE Therapeutics shares in Q1 2022, an estimated $169K.
  • Marshall Wace first reported a position in VYNE Therapeutics in Q1 2021 and held it in 2 quarters.
  • Marshall Wace's VYNE Therapeutics position peaked at $442K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.